AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33831589
Drug: Parenteral opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral opioids as labor analgesia
Trial: 32802108
Drug: Glycyrrhiza glabra
RxNorm normalized name: Glycyrrhiza glabra
DrugBank: Glycyrrhiza glabra (DB14312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhiza glabra syrup (5 cc, two times a day)
Trial: 32802108
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg tablets every 8 hours)
Trial: 36107549
Drug: Ultrasound-guided serratus
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided serratus anterior plane block (SAPB) with 20 mL of 0.25% bupivacaine + general anesthesia
Trial: 32875933
Drug: Matcha green
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matcha green tea powder (3x1 gram capsules per day for three weeks)
Trial: 33428281
Drug: Risankizumab 150
RxNorm normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 150 mg subcutaneous injections at weeks 0, 4, and 16
Trial: 32112738
Drug: Camrelizumab 3
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab 3 mg/kg intravenously every 2 or 3 weeks
Trial: 34992667
Drug: Butorphanol 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 0.02 mg/kg
Trial: 35098674
Drug: LCL161 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCL161 monotherapy (1200 mg)
Trial: 35098674
Drug: LCL161 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCL161 plus paclitaxel (80 mg/m2)
Trial: 35098674
Drug: LCL161 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCL161 monotherapy
Trial: 32563598
Drug: Post-discharge oral
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-discharge oral nutritional supplements (ONS) with dietary advice
Trial: 33041014
Drug: Manual adjustment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual adjustment of norepinephrine infusion (Control)
Trial: 33205662
Drug: Durable Polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durable Polymer Drug-Eluting Stent (DP-DES)
Trial: 33205662
Drug: Biodegradable Polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biodegradable Polymer Drug-Eluting Stent (BP-DES)
Trial: 32002556
Drug: High-dose radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiation (64.8 Gy in 36 fractions)
Trial: 32002556
Drug: Low-dose radiation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiation (50.4 Gy in 28 fractions)
Trial: 36164038
Drug: R-CHOP +
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP + tafasitamab (12 mg/kg intravenously, Days 1, 8, and 15) + LEN (25 mg orally, Days 1-10)
Trial: 33792210
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal treatment (oral hygiene instructions, scaling and root planing)
Trial: 34015014
Drug: TaurolockU (taurolidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TaurolockU (taurolidine heparin locks twice a week combined with taurolidine urokinase locks once a week)
Trial: 34015014
Drug: Control (taurolidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (taurolidine heparin locks thrice weekly)
Trial: 34172071
Drug: Inspiratory and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory and expiratory respiratory muscle training (IEMT) for 8 weeks, consisting of 5 sets of 10 repetitions, three times a day, with increasing training loads weekly
Trial: 32708555
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg·kg−1) for 4 days, acute intake on day 5
Trial: 33484864
Drug: Omadacycline 100
RxNorm normalized name: omadacycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omadacycline 100 mg intravenously (every 12 h for two doses, then every 24 h) with optional transition to 300 mg orally after 3 days
Trial: 33484864
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg intravenously (every 24 h) with optional transition to 400 mg orally after 3 days
Trial: 33420673
Drug: Continuous Energy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Energy Restriction (CER) - average daily energy deficit of 500 kcal
Trial: 35914511
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + Ticagrelor
Trial: 36352445
Drug: Tablet-based video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based video game stimulating cognitive and socio-emotional skills
Trial: 36352445
Drug: Tablet-based game
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet-based game where students draw and paint (control)
Trial: 33228739
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 2 mL/kg of 20% intralipid before aortic cross-unclamping
Trial: 34154367
Drug: omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 fatty acids (4 g daily)
Trial: 35614404
Drug: Home‐Based Multimodality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home‐Based Multimodality Functional Recovery and Metabolic Health Enhancement Program (FES‐LC plus AE and testosterone therapy)
Trial: 35614404
Drug: FES‐LC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FES‐LC plus AE and placebo injections
Trial: 34845002
Drug: Erenumab 140
RxNorm normalized name: Erenumab 140 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab 140 mg monthly
Trial: 32980696
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of treatment protocol of Group A and Group B
Trial: 35157781
Drug: Levetiracetam granules
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam granules (500 mg)
Trial: 35157781
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution of levetiracetam
Trial: 34506883
Drug: Dietary dandelion
RxNorm normalized name: DANDELION
DrugBank: Taraxacum officinale pollen (DB10755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary dandelion flower extract (DFE) at 3 g/kg
Trial: 34506883
Drug: Dietary dandelion
RxNorm normalized name: DANDELION
DrugBank: Taraxacum officinale pollen (DB10755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary dandelion flower extract (DFE) at 2 and 3 g/kg
Trial: 34506883
Drug: Dietary dandelion
RxNorm normalized name: DANDELION
DrugBank: Taraxacum officinale pollen (DB10755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary dandelion flower extract (DFE) at 3 and 4 g/kg
Trial: 34506883
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 g/kg DFE)
Trial: 33836265
Drug: On-treatment ctDNA
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment ctDNA increase
Trial: 35151715
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiotherapy (SABR) - 26 Gy in 2 weekly fractions
Trial: 35151715
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose rate (HDR) brachytherapy - 27 Gy in 2 weekly fractions
Trial: 34534410
Drug: LYR-210 (2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYR-210 (2500 ?g)
Trial: 34534410
Drug: LYR-210 (7500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYR-210 (7500 ?g)
Trial: 36070357
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BoNT‐A) injection
Trial: 32236715
Drug: Glenohumeral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glenohumeral injection of triamcinolone 8 weeks postoperatively
Trial: 32236715
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injection postoperatively
Trial: 32186028
Drug: TwHF cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TwHF cream
Trial: 35747933
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of carbohydrate (30g) and protein (15g + 15g)
Trial: 34352138
Drug: Zuranolone 30
RxNorm normalized name: zuranolone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zuranolone 30 mg
Trial: 36026800
Drug: ABP‐051 stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABP‐051 stimulation therapy
Trial: 34290862
Drug: Sublingual CoQ10
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual CoQ10 (400 mg/d)
Trial: 32170665
Drug: OnabotulinumtoxinA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA with antithrombotic therapy
Trial: 32170665
Drug: OnabotulinumtoxinA without
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA without antithrombotic therapy
Trial: 32170665
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with antithrombotic therapy
Trial: 32170665
Drug: Placebo without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo without antithrombotic therapy
Trial: 32503946
Drug: ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 3 mg/kg
Trial: 32503946
Drug: ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 10 mg/kg (subgroup with asymptomatic brain metastasis)
Trial: 32503946
Drug: ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 3 mg/kg (subgroup with asymptomatic brain metastasis)
Trial: 32503946
Drug: ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 10 mg/kg (wild-type BRAF tumors)
Trial: 32503946
Drug: ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 3 mg/kg (wild-type BRAF tumors)
Trial: 32503946
Drug: ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 10 mg/kg (mutant BRAF tumors)
Trial: 32503946
Drug: ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 3 mg/kg (mutant BRAF tumors)
Trial: 36432453
Drug: Discontinue central
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinue central access at an enteral feeding volume of 100 mL/kg/day
Trial: 36432453
Drug: Standard discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard discontinuation at an enteral feeding volume of 140 mL/kg/day
Trial: 33955599
Drug: Enzalutamide plus
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide plus androgen deprivation therapy
Trial: 34400339
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) at 160 ppm for 30 min twice daily
Trial: 35144945
Drug: Fresh frozen
RxNorm normalized name: Fresh frozen plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh frozen plasma (FFP) (10 mL/kg)
Trial: 34363942
Drug: Discontinuing antibiotic
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuing antibiotic therapy
Trial: 34363942
Drug: Usual strategy
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual strategy of continuing antibiotic treatment
Trial: 38088558
Drug: Ziltivekimab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziltivekimab 7.5 mg
Trial: 38088558
Drug: Ziltivekimab 15
RxNorm normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziltivekimab 15 mg
Trial: 38088558
Drug: Ziltivekimab 30
RxNorm normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziltivekimab 30 mg
Trial: 33739852
Drug: Intensified pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensified pegaspargase (four additional doses at 3-week intervals during consolidation and interim maintenance)
Trial: 33739852
Drug: Standard COG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard COG low-intensity therapy (including two pegaspargase doses during induction and delayed intensification)
Trial: 33739852
Drug: Low-risk patients
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-risk patients (with favorable cytogenetics) compared to standard-risk patients (with identical therapy but without favorable or unfavorable cytogenetics)
Trial: 33739852
Drug: Overall survival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall survival (OS) for standard COG therapy
Trial: 36334430
Drug: Chemically protected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemically protected sodium butyrate (CSB) 1,000 mg/kg
Trial: 36334430
Drug: Antibiotics (enramycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (enramycin 8 mg/kg and aureomycin 100 mg/kg)
Trial: 32699231
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + LSD (100 µg)
Trial: 32699231
Drug: 5-HT2A receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT2A receptor antagonist ketanserin (40 mg) + LSD (100 µg)
Trial: 36071112
Drug: Citalopram (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (8 mg)
Trial: 37902943
Drug: IA 40
RxNorm normalized name: DROXIA 400mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA 40 mg TCA followed by IA 0.07 mg LOR
Trial: 37902943
Drug: IA 0.07
RxNorm normalized name: TRICHOTHECIUM ROSEUM 0.071 g in 20 mL / PASSALORA FULVA 0.071 g in 20 mL / COCHLIOBOLUS SPICIFER 0.071 g in 20 mL / MYROTHECIUM VERRUCARIA 0.071 g in 20 mL / TRICHOPHYTON SCHOENLEINII 0.071 g in 20 mL / Mycogone nigra 0.071 g in 20 mL / NEUROSPORA CRASSA 0.071 g in 20 mL / KHUSKIA ORYZAE 0.071 g in 20 mL / PAECILOMYCES VARIOTII 0.072 g in 20 mL / MICROASCUS BREVICAULIS 0.072 g in 20 mL / HELMINTHOSPORIUM SOLANI 0.072 g in 20 mL / PLEOSPORA TARDA 0.072 g in 20 mL / STREPTOMYCES GRISEUS 0.072 g in 20 mL / TRICHODERMA VIRIDE 0.072 g in 20 mL PERCUTANEOUS INJECTION, SOLUTION [RINKEL MOLD MIX B]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA 0.07 mg LOR followed by IA 40 mg TCA
Trial: 32895744
Drug: Nebulised saccharin
RxNorm normalized name: Saccharin
DrugBank: Saccharin (DB12418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised saccharin solution
Trial: 34184798
Drug: Depot buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot buprenorphine (CAM2038 weekly for 4 weeks then monthly)
Trial: 34184798
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral methadone
Trial: 35769196
Drug: Date seed
RxNorm normalized name: DATE SEED EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Date seed powder (26 g/d)
Trial: 35230053
Drug: High-Dose Pindolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose Pindolol
Trial: 36169433
Drug: Methylphenidate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate treatment (Group B)
Trial: 32530765
Drug: Boost radiotherapy
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boost radiotherapy (36 Gy total dose) after single or tandem autologous stem-cell transplantation
Trial: 32530765
Drug: Single SCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single SCT with boost radiotherapy (36 Gy total dose) for incomplete resection
Trial: 33529381
Drug: Flapless administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flapless administration of enamel matrix derivative (EMD) as adjunct to re‐instrumentation
Trial: 33529381
Drug: Re‐instrumentation without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re‐instrumentation without adjunctive EMD (control)
Trial: 32150296
Drug: Maximum tolerated
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum tolerated dose combinations from the first stage of the trial
Trial: 32150296
Drug: Adaptive randomization
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive randomization of patients to dose combinations
Trial: 36498561
Drug: Platelet-Rich Plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-Rich Plasma (PRP) treatment
Trial: 36043781
Drug: Tadalafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (20 mg single dose)
Trial: 39495582
Drug: P2Y12 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P2Y12 inhibitors
Trial: 33966361
Drug: Liposomal Glutathione
RxNorm normalized name: Liposomal glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal Glutathione (L-GSH)
Trial: 33966361
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro Everolimus treatment
Trial: 33966361
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of L-GSH and Everolimus
Trial: 616117489
Drug: Lomerizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomerizine (10 mg per day)
Trial: 32989916
Drug: Tertiary care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tertiary care multimodal treatment program
Trial: 36109819
Drug: Subcutaneous tunnelling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous tunnelling for PICC placement
Trial: 34335943
Drug: Cetuximab plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab plus chemotherapy (arm A)
Trial: 34335943
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus chemotherapy (arm B)
Trial: 32570059
Drug: Laser group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser group (LG) - photobiomodulation (PBM) using a diode laser (660 nm, 10 J/cm2, 0.28 J per point, 40 mW for intra-oral; 810 nm, 25 J/cm2, 0.7 J per point, 40 mW for extra-oral) applied three times a week during radiotherapy.
Trial: 32570059
Drug: Sham group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham group (SG) - sham treatment with the instrument tip sealed to prevent light passage.
Trial: 35051162
Drug: Ultrasound-guided partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided partial release of the transverse carpal ligament using an 18-G needle
Trial: 33295133
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: One dose (1 g) of IV‐TXA before skin incision + one dose (1.5 g) of IA‐TXA + single dose of IV‐TXA (1 g) for 3 h
Trial: 33295133
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Two doses of IV‐TXA (1 g) for 3 and 6 h
Trial: 33295133
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: Three doses of IV‐TXA (1 g) for 3, 6, and 12 h
Trial: 35854762
Drug: Metformin combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin combined with medroxyprogesterone acetate
Trial: 33765691
Drug: Endothelin receptor
RxNorm normalized name: Endothelin receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin receptor antagonists (ERAs)
Trial: 33960725
Drug: GLPG1205 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1205 10 to 800 mg (single doses)
Trial: 33960725
Drug: GLPG1205 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1205 50 mg (once daily for 14 days)